A standardized, sensitive and universal method for minimal residual disease (MRD) detection in acute myeloid leukemia (AML) is still pending. Although hyperexpression of Wilms' tumor (WT1) gene transcript has been frequently proposed as an MRD marker in AML, wide comparability of the various methods used for evaluating WT1 expression has not been given. We established and standardized a multicenter approach for quantifying WT1 expression by quantitative reverse transcriptase PCR (qRT-PCR), on the basis of a primer/probe set combination at exons 6 and 7. In a series of quality-control rounds, we analyzed 69 childhood AML samples and 47 normal bone marrow (BM) samples from 4 participating centers. Differences in the individual WT1 expressions levels ranged within o0.5 log of the mean in 82% of the cases. In AML samples, the median WT1/1E þ 04 Abelson (ABL) expression was 3.5E þ 03 compared with that of 2.3E þ 01 in healthy BM samples. As 11.5% of childhood AML samples in this cohort harbored WT1 mutations in exon 7, the effect of mutations on WT1 expression has been investigated, showing that mutated cases expressed significantly higher WT1 levels than wild-type cases. Hence, our approach showed high reproducibility and applicability, even in patients with WT1 mutations; therefore, it can be widely used for the quantitation of WT1 expression in future clinical trials.
Introduction
Minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML) has been shown to be prognostically relevant, for the assessment of treatment response and for the early detection of relapse. [1] [2] [3] [4] [5] Specific gene rearrangements, such as PML/RARa, AML1/ETO, CBFB/MYH11, FLT3/ITD and NPM1 mutations, can be used for monitoring MRD. However, fusion gene transcripts are applicable in only 20-30% of patients. Furthermore, ITD is clonally instable, and NPM1 mutations have a low prevalence in children (8-10%). 6 There is accumulating evidence that the transcription factor, WT1, originally described as a tumor-suppressor gene, is a key molecule for tumor proliferation in a large number of human neoplasms, making it suitable both as a universal MRD marker and as a target for therapeutic strategies, such as vaccination. 2, [7] [8] [9] [10] The WT1 gene encodes a zinc-finger transcription regulator located on chromosome 11 that has been implicated in numerous malignancies, such as Wilms' tumor, leukemia, breast, lung, colon and skin cancer. Furthermore, the WT1 gene is a regulator of growth and differentiation during ontogenesis. WT1 hyperexpression is required for uncontrolled proliferation and defective differentiation of leukemic cells. The basis for the abnormal expression of WT1 is not completely clear, although there are accumulating data showing functional consequences of WT1 hyperexpression on the expression of other genes, including cell-cycle promotion, blocking of differentiation and inhibition of apoptosis. 8 WT1 expression has been evaluated as a marker for risk stratification and MRD detection in AML. [1] [2] [3] [4] [5] [11] [12] [13] [14] However, contradictory reports refer to the value of WT1 hyperexpression for monitoring MRD during front-line chemotherapy and after allogeneic stem-cell transplantation. Although many authors describe a strong predictive value, 3 ,4,9,10,15 these findings could not be confirmed by others. 16 Boublikova et al. 17 described an association between WT1 expression below the normal physiological range in bone marrow (BM) and relapse in a proportion of childhood acute lymphoblastic leukemia (ALL) patients.
Recently, mutations throughout the entire WT1 gene were determined to be a novel independent poor-prognostic factor in CN-AML (cytogenetically normal AML), which might potentially influence MRD detection by WT1 expression analysis. [18] [19] [20] [21] [22] [23] [24] As pediatric AML is a rare disease, international cooperation is necessary for monitoring substantial numbers of patients to obtain statistically powerful results. Although various methodologies have been applied in the past, a uniform approach that has been proven to ensure reproducible, accurate and comparable results on a multicenter basis is currently unavailable.
To develop such an approach, the European Study Group on WT1 Expression in Childhood AML that included centers from Frankfurt and Jena (Germany), Monza (Italy) and Prague (Czech Republic) was established.
In this study, we present a quality-controlled standardized approach for an accurate and reproducible quantitation of WT1 expression using quantitative reverse transcriptase PCR (qRT-PCR) and TaqMan chemistry. The assay was designed, tested, evaluated and optimized on a common European multicenter basis, using Abelson (ABL) as a housekeeping gene for normalization. Quantitation was based on WT1-and ABLgene-containing plasmids, both produced in-house. Quality controls (QCs) that included pediatric diagnostic AML samples as well as BM samples from healthy donors (h.BM) were performed to survey the reproducibility and accuracy of the quantitation of WT1 and ABL expressions at the different centers. AML samples were also screened for the presence of WT1 gene mutations to determine the influence of these mutations on WT1 expression level and the ability to perform qRT-PCR.
Materials and methods

Sample processing
Bone marrow samples were collected in sterile EDTA tubes. The initial processing of samples was carried out within the first 24 h after collection. Mononuclear cells were isolated from samples using the Ficoll gradient centrifugation (Density 1.077, Seromed, Biochrom KG Berlin, Germany). RNA isolation was then performed or mononuclear cells were stored at À80 1C for later processing.
RNA isolation
RNA from mononuclear cells was isolated using either the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions (Frankfurt, Jena) or using a modified method as described by Chomczynski and Sacchi 25 (Monza, Prague). The concentration and 260:280 nm ratio of the extracted RNA was determined using spectrophotometry.
Complementary DNA (cDNA) synthesis by reverse transcription (RT) Random hexamer oligonucleotides were used to prime cDNA synthesis by RT (iScript cDNA Synthesis Kit, Bio-Rad, Hercules, CA, USA; MoMLV Reverse Transcriptase, Gibco BRL, Carlsbad, CA, USA; SuperScript II Reverse Transcriptase, Invitrogen, Carlsbad, CA, USA) from 1 mg of total RNA template according to the recommendations from the EAC (Europe Against Cancer) and the BIOMED-1 programs. [26] [27] [28] QRT-PCR primers and probes The fluorescent probe, 5 0 -6-FAM-CAACGCCCATCCTCTGCG GAGCCCA-TAMRA-3 0 (exon 6, nt position: 1230-1254, NM_ 024426), was used as described earlier by Kreuzer et al. 29 The primers and probes were synthesized by TIB Molbiol, Berlin, Germany.
The ABL gene was chosen as a control (housekeeping) gene (CG) to evaluate the amount and amplification of cDNA. Its transcript represents a reliable CG for diagnostic and MRD samples, according to the recommendations of the EAC program. 26, 27, 30, 31 The qRT-PCR primer/probe set for the ABL gene was as follows:
Fwd primer: 5 0 -TGGAGATAACACTCTAAGCATAACTAAAG GT-3 0 (nt position: 228-258, NM_005157); and rvs primer: 5 0 -GATGTAGTTGCTTGGGACCCA-3 0 (nt position: 331-351, NM_005157).
The fluorescent probe, 5'-6-FAM -CCATTTTTGGTTTGGGC TTCACACCAT-TAMRA-3 0 (nt position: 297-323, NM_005157), was used as described earlier by Cilloni et al. 15 The primers and probes were synthesized by TIB Molbiol.
An independent secondary analysis of WT1 expression in AML samples with mutations in exon 7 of the WT1 gene was performed using a qRT-PCR system with a primer/probe set designed to bind at exons 1 and 2 of the WT1 gene. 32 
Plasmids
WT1 plasmid was produced as follows: The WT1 sequence was obtained using primers, WT1 clo S CCACAGCACAGGGTACG AGAG and WT1 clo A AGACCCTTCAAAGCGCCAG (from exon 6 to exon 10) and cloned into the PCR 2.1-TOPO vector. The resulting construct was transformed into TOP10 Escherichia coli strain, using a TOPO TA Cloning Kit (GIBCO BRL). The selected clones were screened for the presence of inserts by PCR. After bulk production, plasmids were extracted and quantified using spectrophotometry.
ABL plasmid was produced as follows: The ABL sequence was cloned into the Phosphorodiamidate morpholino oligomers (PMOS) vector (Amersham-Pharmacia, Buckinghamshire, UK). Selected clones were screened for the presence of inserts by PCR. After bulk production, plasmids were extracted and quantified using spectrophotometry.
The presented qRT-PCR system, including the plasmids, is available for free from our consortium for all interested groups.
Standard dilution series
Plasmid stocks were serially diluted in low-molecular-weight DNA from salmon sperm (Sigma-Aldrich, St Louis, MO, USA) having a final concentration of 0.2 g l À1 . WT1 plasmid dilutions for absolute quantitation of standard dilutions were prepared using final concentrations covering the range of five 10-fold dilution steps (copies per ml) as follows: 2.5E þ 05, 2.5E þ 04, 2.5E þ 03, 2.5E þ 02, 2.5E þ 01 and 2.5E þ 00. ABL plasmid dilutions for normalization of standard dilutions were prepared using final concentrations covering the range of five 10-fold dilution steps (copies per ml) as follows: 2.5E þ 06, 2.5E þ 05, 2.5E þ 04, 2.5E þ 03, 2.5E þ 02 and 2.5E þ 01. Theoretically, the slope of standard curves should be À3.3, as 10-fold dilutions were used. In practice, the slope was between À3.2 and À3.7, which was accepted as long as the correlation coefficient was X0.99.
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QRT-PCR conditions
qRT-PCR analyses were performed using the ABI PRISM 7700/ 7900 Sequence Detector (Applied Biosystems, Foster City, CA, USA) in Frankfurt, Jena and Monza and the iQ/iQ5 Cycler Realtime PCR Detection System (Bio-Rad) in Frankfurt and Prague.
PCR amplification parameters were as follows: Reaction mix: 100 ng template cDNA, 2X TaqMan Universal PCR Master Mix (Applied Biosystems), 250 nM of each fwd and rvs WT1 primer, 100 nM of WT1 fluorescent probe; and 300nM of each fwd and rvs ABL primer, 200 nM of ABL fluorescent probe. A final volume of 25ml was obtained. PCR conditions: 2 minutes at 50 1C followed by 10 min at 95 1C and 50 two-step amplification cycles consisting of 15 s at 95 1C followed by 60 s at 60 1C. QRT-PCR of WT1 and ABL plasmid dilutions, nontemplate control, as well as the quantitation of WT1 and ABL expression of respective samples were performed in duplicates.
Quantitation of WT1 and ABL expressionFsoftware
The qRT-PCR data were analyzed using the ABI PRISM 7700/7900 Sequence Detector Software and Bio-Rad iQ/iQ5 Cycler Optical System Software. WT1 and ABL expressions were given in copy numbers according to the standard curves of the plasmids. WT1 expression was reported as a ratio of the WT1 copies/1E þ 04 ABL copies.
Screening for mutations
Screening for mutations in the WT1 gene was performed in Rotterdam on DNA and cDNA from 33/61 and 28/61 AML samples, respectively, as described earlier by Hollink et al. 18 
Statistical analysisFsoftware
Statistical analyses were performed using the software package 'R', a language and environment for statistical computing and graphics (The R Foundation for Statistical Computing, Vienna, Austria). 34 
Results
Quality control, patients and samples
Six semi-annual QCs were performed to establish an agreement on the common approach and to survey the reproducibility and accuracy of the quantitation of WT1 and ABL expressions from four independent different centers ( Table 1) . Primers and probes, as well as plasmids and cDNA from diagnostic pediatric AML and normal BM samples from voluntary healthy donors, were shipped from each participating center to all other centers for performing simultaneous analyses. Each QC phase ended with a collaborative meeting.
Patients and samples
We analyzed 116 samples that comprised 69 diagnostic AML samples and 47 h.BM samples. The distribution (n) of the French-American-British (FAB) classification of subtypes of AML samples was as follows: M1: 11; M2: 20; M3: 5; M4: 7; M5: 14; M6: 1; M7: 2; bi-phenotypic: 3; and unclassified: 6. The median age of the h.BM donors was 24 years (1-54 years) and the sex distribution was as follows: female: 13; male: 31; and unknown: 3. Informed consent was obtained from patients as well as from healthy donors before sample harvesting. AML patients were treated according to AML-BFM 2004 and AML-AIEOP 2002/01 trials.
Reproducibility and quantifiable limit of standard dilutions
When considering a o1 cycle-threshold (CT) difference between replicates, intra-and inter-assay quantitation of WT1 and ABL gene transcripts was reproducible in the range between 2.5E þ 05 and 2.5E þ 01 copies of the WT1 plasmid ( Figure 1a ) and in the range between 2.5E þ 06 and 2.5E þ 01 copies of the ABL plasmid (Figure 1b) . The quantifiable limit, denoted as the lowest possible threshold 35 was 25 copies for both the plasmids.
Reproducibility and comparability of WT1 expression analyses
Overall, 116 samples comprising 69 diagnostic AML samples and 47 h.BM samples were analyzed at each of the four participating centers. In Figure 2a , WT1 expression of a respective sample analyzed at each center (reported as WT1 copies/1E þ 04 ABL copies) was plotted against the mean of all centers. Comparability of measurements did not depend on the level of WT1/1E þ 04 ABL expression for AML patients. h.BM showed a slightly larger s.d. between measurements from the four centers (Wilcoxon test, Po0.001). Individual WT1/1E þ 04 ABL expression of a respective sample analyzed at each of the four centers was within a 0.5 log range of the mean in 82% of the samples (AML: 91% and h.BM: 68%). Pairwise differences (AML, n ¼ 403 and h.BM, n ¼ 194) between logarithmic WT1/1E þ 04 ABL expressions analyzed at the four centers were o1 in 95% of the samples (AML: 98% and h.BM: 88%) and o0.5 in 73% of the samples (AML: 79% and h.BM: 59%; Figure 2b ).
WT1 expression in AML and healthy bone marrow samples
We compared four individual WT1/1E þ 04 ABL expression measurements obtained from each diagnostic pediatric AML sample with respective expression levels obtained from h.BM ( Figure 3) . The difference in WT1 expression between these two groups was highly significant (t-test based on mean expression per sample, Po0.001). The following WT1/1E þ 04 ABL expression quantiles were observed for pediatric diagnostic AML samples: 5% 8.1E þ 00; 25% 7.6E þ 02; 50% 3.5E þ 03; 75% 9.7E þ 03; 95% 3.9E þ 04; and for h.BM WT1 expression Impact of WT1 gene mutations on standardized European qRT-PCR system AM Willasch et al quantiles: 5% 1.0E þ 00; 25% 9.2E þ 00; 50% 2.3E þ 01; 75% 5.4E þ 01; 95% 1.4E þ 02. The 95% quantile for WT1/1E þ 04 ABL copies in AML samples was 3.9E þ 04, whereas that in h.BM samples was 1.4E þ 02 (140 copies); therefore, 140 copies were defined as the threshold for WT1 expression in h.BM. Although only 5% of h.BM-WT1 expression levels showed values above this threshold, as many as 86% of the diagnostic AML WT1 expression levels were above this quantile. Overall, 46 (67%) and 13 (19%) diagnostic AML samples expressed WT1 1 log and 2 logs above the threshold for WT1 expression in h.BM, respectively (denoted by mean WT1/1E þ 04 ABL expression of each sample, Figure 2a and 3) . As much as 63 (91.3%), 59 (85.5%), 50 (72.5%) and 17 (24.6%) diagnostic AML samples out of 69 expressed WT1 1, 2, 3 and 4 logs above the baseline of 1 WT1 copy/1E þ 04 ABL copies, respectively (denoted by mean WT1/1E þ 04 ABL expression of each sample).
WT1 expression in healthy BM samples according to age
For 43/47 h.BM samples, the age of the donor was known and therefore, could be included in the analysis of WT1 expression in age subgroups. The following WT1/1E þ 04 ABL expression quantiles in h.BM samples were observed for donors r18 years of age (n ¼ 16): 5% 1.8E þ 00; 25% 7.0E þ 00; 50% 2.3E þ 01; 75% 2.8E þ 01; 95% 7.7E þ 01; and for donors 418 years of age (n ¼ 27): 5% 1.0E þ 00; 25% 6.5E þ 00; 50% 1.3E þ 01; 75% 4.7E þ 01; 95% 6.7E þ 01. No significant difference was observed between the two cohorts ( Figure 4 ).
WT1 expression in the WT1 gene-mutated versus wild-type AML samples
Mutations in exon 7 of the WT1 gene were screened in 61 of the 69 diagnostic pediatric AML samples. We identified seven WT1 mutated samples (Table 2) , corresponding to a prevalence of 11.5% in this pediatric cohort. To gain more knowledge about the correlation between WT1 expression and mutational status, we analyzed WT1 expression in those 7 cases, as well as in an additional 11 pediatric AML samples collected after completing the QC rounds. Consequently, a correlation of WT1 expression and mutational status was performed in 18 AML samples mutated in exon 7 and 54 wild-type samples. The following WT1/1E þ 04 ABL expression quantiles were observed for mutated samples: 5% 2.0E þ 03; 25% 4.3E þ 03; 50% 6.8E þ 03; 75% 1.2E þ 04; 95% 2.3E þ 04; and for wild-type samples: 5% 7.9E þ 00; 25% 5.5E þ 02; 50% 2.7E þ 03; 75% Impact of WT1 gene mutations on standardized European qRT-PCR system AM Willasch et al 9.0E þ 03; 95% 3.5E þ 04 ( Figure 5 ). As denoted by quantiles, WT1 expression of the mutated samples was significantly higher than in wild-type samples (Po0.01) similar to the highly expressing subgroup of wild-type AML cases.
The WT1 hyperexpression of exon 7 mutated cases was further confirmed in 5/18 cases for whom material was available, by applying a distinct qRT-PCR system located at exons 1 and 2 of the WT1 gene (data not shown). In this cohort, 7/18 WT1 exon 7 mutated samples harbored the mutation exactly at the binding site of the reverse primer used in QC rounds. The comparison of WT1 expression in samples with (mean WT1 expression: 3.85E þ 03, s.d.: ± 130) or without mutation (mean WT1 expression: 3.82E þ 03, s.d.: ± 130) at the binding site of the reverse primer revealed no difference. Interestingly, the only sample with a homozygous mutation in exon 7 revealed a substantial WT1 expression (5.4E þ 03).
Discussion
The WT1 gene hyperexpression and its kinetics of reduction during therapy have been repeatedly proposed as a marker for risk stratification and MRD detection in AML. [1] [2] [3] [4] [5] 11, 12 WT1 expression was most frequently quantified by qRT-PCR applying TaqMan chemistry with various methodologies. However, a uniform approach proven to be reproducible, accurate and comparable on a multicenter basis is currently unavailable. For this purpose, the European Study Group on WT1 Expression in Childhood AML comprising centers from Frankfurt and Jena, Monza and Prague was established.
In this study, we present for the first time a quality-controlled multicenter evaluation of a qRT-PCR-based method to quantify WT1 expression with regard to reproducibility, quantifiable limit and applicability of the results. QCs comprised 116 samples consisting of 69 pediatric AML and 47 h.BM donor samples. Analyses that were performed, applying a uniform primers and probe system with TaqMan chemistry and in-house plasmids, showed reproducible quantitation of WT1 and ABL gene transcripts up to 25 copies for both the plasmids. WT1 expression of a respective sample measured from each of the four centers was within the 0.5 log range of the mean in 82% of samples (AML: 91% and h.BM: 68%) and within the 1 log difference in 95% of samples (AML: 98% and h.BM: 88%) indicating accuracy and reproducibility. This proves that this method of WT1-based MRD analyses can be applied in multicenter clinical trials.
In pediatric diagnostic AML samples, the median WT1/ 1E þ 04 ABL expression was 3.5E þ 03, whereas the median expression for h.BM was 2.3E þ 01. Interestingly, 86% of the diagnostic AML cases showed a WT1/1E þ 04 ABL level higher than the 95% quantile of h.BM, which was 140 WT1 copies/ 1E þ 04 ABL copies.
To our knowledge this is the largest cohort of h.BM samples presented so far, in which the analysis of WT1 expression was performed. In concordance with earlier reports on a lower number of samples, 1, 10 these results indicate the great variability of WT1 expression in normal h.BM. As a consequence, the sensitivity range for WT1 expression as an MRD marker, although having some clinical usefulness, could be limited. More precisely, when considering the 95% quantile of the h.BM values as a threshold (140 WT1/1E þ 04 ABL copies), 67 and 19% of the AML samples expressed WT1 at 1 and 2 logs, respectively above the normal h.BM level, whereas no sample expressed WT1 at 3 logs above the WT1 level of h.BM. This is in concordance with earlier publications. 1 In particular as CN-AML revealed high WT1 expression in earlier reports, 1 WT1 could be of major clinical importance in this important AML subgroup, which lacks other molecular methods for MRD monitoring. Furthermore, the applicability of WT1 as an MRD marker must be evaluated in a larger cohort of AML patients as it is unknown whether the WT1 expression of this AML cohort was representative.
Mutations throughout the entire WT1 gene were detected as a novel independent poor-prognostic factor in AML, and in particular in CN-AML, with a potential effect on MRD detection by WT1 expression analysis. [18] [19] [20] [21] [22] [23] [24] Hotspots for mutations were recently detected and included, among others, exon 7 of the WT1 gene. 18, 19, 22 As the reverse primer of our qRT-PCR approach spans exons 6 and 7, mutations in exon 7 might theoretically affect the detection of WT1 expression, if a potential mutation is located at the binding site of the primer. To address this question, we screened for mutations within exon 7 of the WT1 gene and correlated WT1 expression and mutational status. Of the 61 pediatric AML patients who were analyzed, 7 (11.5%) revealed mutations in agreement with earlier publications. 18, 19, 22 Mutations were frame-shift mutations, predominantly caused by insertions. All samples with mutations in the WT1 gene revealed substantial WT1 expression, as quantified by our qRT-PCR system on exons 6 and 7. Although WT1 wild-type samples comprised a subgroup with low WT1 expression, WT1 expression was high in all mutated Impact of WT1 gene mutations on standardized European qRT-PCR system AM Willasch et al samples that were at a similar level as that of wild-type samples with higher WT1 expression. To strengthen these findings, we evaluated WT1 expression analysis in samples with mutations in exon 7 by applying a distinct qRT-PCR system located at exons 1 and 2. 32 Using this primer/probe set, we could further confirm high WT1 levels in WT1 exon 7 mutated cases, proving that the qRT-PCR system on exons 6 and 7, used in the QC rounds, was robust enough to be applied for WT1 expression detection, independently on the mutational status. In this cohort, 7/18 samples carried the mutation in exon 7 exactly at the reverse primer binding site. However, the correlation of WT1 expression in samples with or without mutation at the reverse primer binding site revealed no difference indicating that the effect of mutation on primer annealing could be limited. In addition, the heterozygous status of the mutation might also explain the unaffected WT1 qRT-PCR levels. One might postulate that in 17/18 patient samples, which revealed a heterozygous mutation in exon 7, the expression of the unaffected allele was detected fully by qRT-PCR. Interestingly, the sample with a homozygous mutation in exon 7 revealed a substantial WT1 expression, indicating that even homozygous mutations at the binding site of the primer could not significantly affect qRT-PCR. Furthermore, as a homozygous mutation in the WT1 gene was a rare event in our cohort (1/18, 5.6% in WT1 mutated samples), as well as in the literature (0.7% in diagnostic pediatric AML samples and 5.7% in WT1 mutated samples), 18 its potential effect on WT1 qRT-PCR is negligible. Similarly, WT1 expression could also be quantified in cases that gain the WT1 mutation as a progression event in the course of the disease.
In summary, we hereby presented for the first time a qualitycontrolled system to quantify WT1 expression by qRT-PCR, which was designed, tested, evaluated and optimized on a European multicenter basis, applying in-house plasmids for quantitation (WT1) and normalization (ABL). The approach ensured high reproducibility, accuracy and comparability of results between the centers. Diagnostic pediatric AML samples harboring WT1 gene mutations in exon 7 revealed significantly higher WT1 expression compared with that of wild-type samples. Furthermore, mutations in the WT1 gene at the exact binding position of the reverse primer did not significantly affect WT1 expression detection by qRT-PCR in this cohort.
This system can be used in prospective multicenter trials for assessing the additional prognostic effect of WT1 expression to the existing prognostic factors (that is, cytogenetics, response to induction chemotherapy) and for evaluating whether monitoring MRD by WT1 in the absence of alternative markers could be useful for a better stratification and outcome prediction for AML patients. The presented qRT-PCR system, including the plasmids, is available for free from our consortium for all interested groups.
